EcoDrugPlus

Solute Carrier Family 22 Member 12

Ensembl ID : ENSMOCG00000018357
Gene Symbol: SLC22A12
3 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSMOCG00000021104
Gene Symbol: SLC22A6
3 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSMOCG00000011371
Gene Symbol: SLC22A8
3 Cross references
310 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMOCG00000020636
Gene Symbol: SLC29A1
3 Cross references
284 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSMOCG00000011689
Gene Symbol: SLC6A1
3 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSMOCG00000016144
Gene Symbol: SLC6A2
3 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSMOCG00000000701
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSMOCG00000004407
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSMOCG00000012292
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSMOCG00000016773
Gene Symbol: SLC9A3
3 Cross references
234 Possible Orthologues:

Somatostatin Receptor 1

Ensembl ID : ENSMOCG00000018730
Gene Symbol: SSTR1
3 Cross references
158 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSMOCG00000016578
Gene Symbol: SSTR2
3 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).